Ancilia Biosciences
- Biotech or pharma, therapeutic R&D
Bacterial therapies have vast potential to treat a wide range of diseases, but have fallen short in the clinic. Ancilia identified a critical obstacle to the success of bacterial therapies – widespread viruses that prevent their survival and efficacy. Ancilia is the first company leveraging bacteria's own immune system - CRISPR-Cas - to protect bacteria from destructive viruses and enable their efficacy across broad indications.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}